Acute levodopa administration reduces cortisol release in patients with Parkinson’s disease Article First Online: 24 August 2006 Received: 26 March 2006 Accepted: 03 July 2006 DOI:
Cite this article as: Müller, T., Welnic, J. & Muhlack, S. J Neural Transm (2007) 114: 347. doi:10.1007/s00702-006-0552-0 Summary.
Levodopa (LD) application improves motor symptoms in patients with Parkinson’s disease (PD) patients. Little is known on further effects of LD, which induced lower plasma levels of cortisol and lower serotonergic activity in certain brain areas of fish. Objectives of this trial were to analyse levels of cortisol, LD and 3-O-methyldopa (3-OMD) after administration of LD/benserazide in long term treated PD patients. 12 PD patients, taken off their regular treatment for at least 12 hours, received soluble 200 mg LD/50 mg benserazide under stress free conditions. Motor symptoms improved, LD and 3-OMD levels increased, whereas cortisol concentrations started to decrease significantly 30 minutes after LD intake. This reduced cortisol release may result from an overflow of exogenous LD in the brainstem. This hypothetically causes an reduced 5-HT content in neurons projecting to the hypothalamic structures, which are involved in the partial 5-HT dependent central regulation of peripheral cortisol release.
Keywords: Parkinson’s disease, levodopa, cortisol References Braak, H, Rub, U, Gai, WP, Del Tredici, K 2003 Idiopathic Parkinson’s disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen J Neural Transm 110 517 536 PubMed CrossRef Google Scholar Garcia-Borreguero, D, Larrosa, O, Granizo, JJ, de la, LY, Hening, WA 2004 Circadian variation in neuroendocrine response to L-dopa in patients with restless legs syndrome Sleep 27 669 673 PubMed Google Scholar Halliday, GM, Blumbergs, PC, Cotton, RG, Blessing, WW, Geffen, LB 1990 Loss of brainstem serotonin- and substance P-containing neurons in Parkinson’s disease Brain Res 510 104 107 PubMed CrossRef Google Scholar Happe, S, Tings, T, Helmschmied, K, Neubert, K, Wuttke, W, Paulus, W, Trenkwalder, C 2004 Levodopa treatment does not affect low-dose apomorphine test in patients with Parkinson’s disease Mov Disord 19 1511 1515 PubMed CrossRef Google Scholar Hoglund, E, Kolm, N, Winberg, S 2001 Stress-induced changes in brain serotonergic activity, plasma cortisol and aggressive behavior in Arctic charr (Salvelinus alpinus) is counteracted by L-DOPA Physiol Behav 74 381 389 PubMed CrossRef Google Scholar Lesch, KP, Hoh, A, Schulte, HM, Osterheider, M, Müller, T 1991 Long-term fluoxetine treatment decreases 5-HT1A receptor responsivity in obsessive-compulsive disorder Psychopharmacology (Berl) 105 415 420 CrossRef Google Scholar Lesch, KP, Wiesmann, M, Hoh, A, Müller, T, Disselkamp-Tietze, J, Osterheider, M, Schulte, HM 1992 5-HT1A receptor-effector system responsivity in panic disorder Psychopharmacology (Berl) 106 111 117 CrossRef Google Scholar Lopez, A, Munoz, A, Guerra, MJ, Labandeira-Garcia, JL 2001 Mechanisms of the effects of exogenous levodopa on the dopamine-denervated striatum Neuroscience 103 639 651 PubMed CrossRef Google Scholar Melamed, E, Hefti, F, Pettibone, DJ, Liebman, J, Wurtman, RJ 1981 Aromatic L-amino acid decarboxylase in rat corpus striatum: implications for action of L-dopa in parkinsonism Neurology 31 651 655 PubMed Google Scholar Melamed, E, Hefti, F, Wurtman, RJ 1980 Nonaminergic striatal neurons convert exogenous L-dopa to dopamine in parkinsonism Ann Neurol 8 558 563 PubMed CrossRef Google Scholar Muhlack, S, Woitalla, D, Welnic, J, Twiehaus, S, Przuntek, H, Müller, T 2004 Chronic levodopa intake increases levodopa plasma bioavailability in patients with Parkinson’s disease Neurosci Lett 363 284 287 PubMed CrossRef Google Scholar Müller, T, Erdmann, C, Muhlack, S, Bremen, D, Przuntek, H, Woitalla, D 2006 Inhibition of catechol-O-methyltransferase contributes to more stable levodopa plasma levels Mov Disord 21 332 336 PubMed CrossRef Google Scholar Osei-Owusu, P, James, A, Crane, J, Scrogin, KE 2005 5-Hydroxytryptamine 1A receptors in the paraventricular nucleus of the hypothalamus mediate oxytocin and adrenocorticotropin hormone release and some behavioral components of the serotonin syndrome J Pharmacol Exp Ther 313 1324 1330 PubMed CrossRef Google Scholar Philippi, H, Pohlenz, J, Grimm, W, Koffler, T, Schonberger, W 2000 Simultaneous stimulation of growth hormone, adrenocorticotropin and cortisol with L-dopa/L-carbidopa and propranolol in children of short stature Acta Paediatr 89 442 446 PubMed CrossRef Google Scholar Sabbe, B, Hulstijn, W, Maes, M, Pier, M, Scharpe, S, Zitman, F 2004 Psychomotor, neuroendocrine and behavioural effects after oral administration of levodopa in normal volunteers Psychiatry Res 128 103 106 PubMed CrossRef Google Scholar Schüle, C, Baghai, TC, Eser, D, Zwanzger, P, Jordan, M, Buechs, R, Rupprecht, R 2006 Time course of hypothalamic-pituitary-adrenocoertical axis activity during treatment with reboxitine and mirtazapine in depressed patients Psychopharmacology 186 601 611 PubMed CrossRef Google Scholar Vega, GJ, Miranda, RA, Martinez, G, Torrero, MV, Lopez, dJ 2003 Hyperpigmentation mimicking Laugier syndrome, levodopa therapy and Addison’s disease J Eur Acad Dermatol Venereol 17 324 327 CrossRef Google Scholar Vizner, B, Reiner, Z, Sekso, M 1983 Effect of L-dopa on growth hormone, glucose, insulin, and cortisol response in obese subjects Exp Clin Endocrinol 81 41 48 PubMed CrossRef Google Scholar Vogel, HP, Ketsche, R 1986 Effect of hypoglycaemia, TRH and levodopa on plasma growth hormone, prolactin, thyrotropin and cortisol in Parkinson’s disease before and during therapy J Neurol 233 149 152 PubMed CrossRef Google Scholar Volpi, R, Caffarra, P, Scaglioni, A, Maestri, D, Chiodera, P, Coiro, V 1994 Restoration of ACTH/cortisol and LH responses to naloxone by chronic dopaminergic treatment in Parkinson’s disease J Neural Transm Park Dis Dement Sect 7 1 11 PubMed CrossRef Google Scholar